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Background: Knowledge of factors that contribute to non-persistence with disease modifying anti-rheumatic drugs
(NP) is essential to improve rheumatoid arthritis (RA) outcomes. Aims of the study were to investigate patient’s
motivations and risk factors for NP in a cohort of early RA patients.
Methods: Up to September 2012, data from 149 patients, who had at least 1 year of follow-up, at least one drug
indication, and at least 2 consecutive six-months-apart rheumatic evaluations that included assessment of compli-
ance were reviewed. NP and patient’s motivations of NP were evaluated according to a questionnaire. NP was
defined when patients referred that they had completely stop RA medication, “Sometimes”, “Almost always” or
“Always”. Patients had to pay for their medication.
Descriptive statistics and logistic regression models were used. Statistical significance was set at a p value of less
than 0.05. The study was approved by the internal review board.
Results: Up to cut-off, 715 questionnaires were applied to 149 patients, who had follow-up of 58.7 ± 27.9 months
and were indicated 2.4 ± 0.7 DMARDs/patient/follow-up.
Patients were most frequently female (88.6%), middle-aged ([mean ± SD] age of 38.5 ± 12.8 years) with lower-
middle/lower socio-economic status (87.9%) and scholarship of 11 ± 3.9 years.
Ninety-nine (66.4%) patients were NP and filled 330 questionnaires. Multivariate analysis showed that years of
formal education (OR: 1.12, 95% CI: 1.1-1.24, p = 0.03), perception of at least some difficulty to find arthritis
medication (OR: 5.68, 95% CI: 2.48-13, p = 0.000) and perception that arthritis medication is expensive (OR: 5.27,
95% CI: 2.1-13.84, p = 0.001) at the first evaluation of patient’s compliance were all predictors of NP.
Among the 99 NP patients, 25 (25.3%) were recurrent-NP and accumulated more disease activity. The combination
of both reasons of NP (“Because it was not available at the drugstore” and “Because the medication is very expen-
sive”) when selected at the first evaluation of compliance was the only variable to predict recurrent NP, OR: 4.8,
95% CI: 1.1-20.8, p = 0.04.
Conclusions: Health systems should provide (first line) treatment for RA as a strategy to improve compliance with
therapy and clinical outcomes, particularly in vulnerable populations.* Correspondence: virtichu@gmail.com
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Rheumatoid arthritis (RA) is a chronic inflammatory
disease that may result in significant disability, morbidity
and increased mortality [1-3]. Patients from Latin-
America present unique and distinctive epidemiological,
serological and clinical features regarding their disease.
Published literature highlights a lower prevalence [4], a
younger age at presentation [4,5] and a less severe clin-
ical expression [5] when compared to Caucasians.
Current RA treatment guidelines recommend early
aggressive management with disease modifying anti-
rheumatic drugs (DMARDs) in order to improve
patient’s outcomes. However, poor compliance with ther-
apy is a substantial problem that affects 20% to 70% of
the patients during follow-up [5-16]. Local experience
with a cohort of Mexican Mestizo patients with early
disease have confirmed these data and additionally
shown that poor compliance with traditional DMARDs
was associated with increased disease’s flares, decreased
rates of remission and worse patient-reported outcomes
[5,17,18]. The impact of inadequate therapy behavior in
(early) RA patient’s outcomes may be further amplified
by the fact that almost all the patients who had poor
compliance with drugs eventually dropped out of treat-
ment completely [19]. Furthermore, as a result of
undetected or unreported therapeutic non-compliance,
physicians may recommend a more complex regimen,
which may increase costs and adverse events risks.
Many factors have been related to poor compliance
with drugs in patients with RA [20] and include younger
age [9,14], male sex [13,14], belonging to ethnic minority
[19], lower education [10], side effects [10], availability
of financial resources and social support [11], medica-
tion taking behavior and beliefs [12], increased disability
[13], better perceived health status at the beginning [6],
poor quality of contact with health professionals [13],
poor personal knowledge about the disease and its treat-
ment [13] and class of DMARDs [8,15]. Published data
are obtained from studies performed in developed coun-
tries and in populations predominantly Caucasians.
In 2004, we establish an Early Arthritis Clinic in a re-
ferral Centre for Rheumatic Diseases in México City.
Since the beginning, patient’s medication behavior has
been assessed, initially through a structured interview
and since November 2008 through an instrument locally
designed, the Compliance Questionnaire (CQ), that eval-
uates both constructs, adherence with and persistence
(P) on therapy and investigates patient’s motivations of
inadequate persistence with therapy [16].
In addition to the distinctive features above men-
tioned, RA patients from Latin-America are frequently
uninsured, had a low socio-economical status and are
less educated than RA patients from developed countries
that may additionally impact compliance and outcomes.From the perspective of achieving desirable clinical out-
comes, the negative effect of poor compliance with
DMARDs needs to be minimized. However, in order to
formulate effective strategies to contain the problem
there is a need to investigate the factors that contribute
to poor compliance. The aims of the study were:
1. To investigate most frequent patient’s motivations
for non-persistence with disease modifying anti-
rheumatic drugs (NP) in early RA Mexican Mestizo
patients.
2. To identify risk factors of both, NP and recurrent NP.
Methods
Setting and study population
The early arthritis Clinic at the Instituto Nacional de
Ciencias Médicas y Nutrición was initiated in 2004.
Patients entering the Clinic had disease duration of less
than a year when first evaluated and no specific rheum-
atic diagnosis but with RA. Patients are evaluated every
two months during the first 2 years of follow-up and
thereafter every 2, 4 or 6 (fixed for all the patients from
the baseline evaluation) months depending on patients
and disease characteristics. Treatment is prescribed by
the rheumatologist in charge of the Clinic and is “treat
to target” oriented.
Our Center belongs to the National Institutes of
Health from México. Patients had health expenditures
government coverage depending on their incomes;
coverage varies from 0 to 100%. Most of the patients
(70%) had 70% of their expenditures covered. Costs that
are partially covered include: medical consultations, hos-
pitalizations, emergency room and critical care unit,
laboratory and all the diagnostic procedures available.
Patients need to pay for their medication and these are
not provided by the local pharmacy (unless patients are
hospitalized and if available).
Rheumatic evaluations
At study entry a complete medical history and demo-
graphic data are recorded along with disease specific
autoantibodies. Medical evaluations are standardized
and included swollen and tender joint counts, acute
reactant-phase determinations, patient- and physician-
reported outcomes, comorbidity, and treatment’s assess-
ment (name/s, dose/s and schedule/s of all drug/s they
were taking since last visit) along with the evaluation of
compliance with therapy.
Therapy behavior evaluation
Since 2008, the CQ is applied at fixed- six month inter-
vals to all the patients. The CQ is a 22-items question-
naire (Additional file 1) which evaluates both adherence
with and persistence on therapy. Briefly, Items 1 and 2
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the use of alternative medicine; items 5 and 6 evaluate
patient-physician relationship; in item 7 patients qualify
the quality of physician’s evaluation and central labora-
tory facilities; item 8 evaluates availability of medication
at the drugstores and item 9 evaluates medication cost
patient’s perception, both of them use Likert scales; in
items 12 to 14, patients use a Likert scale to evaluate
adherence to DMARD therapy; items 15, 17, 19 and 21
investigate patient’s knowledge about the disease; finally,
items 16, 18, 20 and 22 determine the level of social
support.
In item 10, patients use a Likert scale (0 to 4) to deter-
mine NP; patients who scored item 10 as 1, 2, 3 or 4 are
directed to answer item 11 mean while those who score
it as 0 are directed to proceed to item 12; item 11 inves-
tigates patient’s reasons of inadequate medication taking
behavior and includes 15 predefined answers (most of
them obtained from literature review) and one open
answer.
Performance of the CQ has shown high sensitivity and
satisfactory specificity to detect persistence on DMARDs
[17]. CQ is fulfilled without help by 95% of the patients.
Definitions
Disease activity was defined according to cut-offs of the
Disease Activity Score, when 28 joints are examined
(DAS28), [21,22].
Disability was evaluated according to the HAQ [23].
A patient was considered to be Persistent if in item 10
“In the past 6 months, how often did you completely
stop taking your medication? “ boxes 0 (“Never”) or 1
(“Almost never”) were filled.
A patient was considered to be NP if in tem 10 boxes
2 (“Sometimes”), 3 (“Almost always”) and 4 (“Always”)
were filled.
A patient was considered to be recurrent-NP if he/she
was defined as NP at every time the CQ was applied.
Ethics
The study was approved by the internal review board
(Comité de Ética en Investigación del Instituto Nacional
de Ciencias Médicas y Nutrición Salvador Zubirán).
Written informed consent was obtained in order to have
patient’s charts reviewed and data presented in scientific
forums or published.
Statistics
Student t test, one-way ANOVA and X2 were used for
normally distributed variables and Mann–Whitney U for
non-normally distributed variables.
To identify baseline predictors for NP and recurrent-
NP, logistic regression models were used. Those vari-
ables bivariately showing a significance level of p ≤ 0.05were included into a regression model. Previously, cor-
relation between selected variables was analyzed. The
full multivariate model was reduced by stepwise removal
of baseline variables with a significance level of p ≤ 0.05.
Statistical analysis was performed using the SPSS/PC
program (v.12.0; Chicago IL). Statistical significance was
set at a p value of less than 0.05.
From the present report, data from patients with at
least 1 year of follow-up, at least one DMARD indication
over follow-up, and at least 2 consecutive six-months-
apart evaluations for compliance were reviewed. Up to
September 2012, 149 patients met the inclusion criteria,
which corresponded to 93% of the population of the
Early Arthritis Clinic.
Results
Characteristics of the population
Up to cut-off, 715 CQ were applied to 149 early RA
patients who had (mean ± SD) follow-up of 58.7 ±
27.9 months and were indicated (mean ± SD) 2.4 ± 0.7
number of DMARDs/patient/follow-up. Main character-
istics of the patients at cohort inclusion are summarized
in Table 1.
Patient’s motivations of NP
Among the 715 CQ applied, 330 (46.2%) were classified
as NP. Table 2 exhibits patient´s motivations and their
frequencies.
Every evaluation of compliance was performed as part
of a complete rheumatic assessment which included dis-
ease activity evaluation as per DAS28. Accordingly, pa-
tients were classified as in remission (DAS28 ≤ 2.6) in
109 out of 330 evaluations and with disease activity in
the remaining 221 evaluations. There were subtle differ-
ences in patient’s motivations of NP between active pa-
tients and patients who achieved remission: formers
referred most frequently “I was not at home when I had
to take my medication” and “nobody reminded me to
take my medication” than their counterparts, as shown
in Table 2.
Predictors of NP
Ninety-nine (66.4%) patients were classified as NP at
some point during their follow-up and filled 330 CQs,
meanwhile 50 were classified as persistent (33.6%) and
filled 385 CQs. P and NP patients were compared. No
differences were found between groups regarding age,
percentage of females, residence, occupation, marital sta-
tus, health coverage and baseline percentage of patients
with RF, baseline -disease activity,- comorbidity and –
treatment, and cumulative-comorbidity and -treatment
(data not shown). Nonetheless, NP patients had more
years of formal education, longer follow-up, had more
antibodies to cyclic citrullinated peptides (ACCP) and





Females, N° (%) 132 (88.6%)
Age at baseline, years, mean ± SD 38.5 ± 12.8
Years of education, mean ± SD 11 ± 3.9




Occupation of the patients, N° (% )
Formal occupation 56 (37.6)
Housewife 54 (36.2)
Willing to work 20 (13.4)
Students 12 (8.1)
Informal occupation 7 (4.7)
% of health expenditures with government coverage
N° (%) of patients with 90% coverage 3 (2)
N° (%) of patients with 80% coverage 25 (16.8)
N° (%) of patients with 70% coverage 104 (69.8)
N° (%) of patients with 60% coverage 17 (11.4)
Disease specific autoantibodies
N° (%) of patients with Rheumatoid Factor 117 (78.5)
N° (%) of patients with antibodies to cyclic citrullinated
proteins
117 (78.5)
Disease characteristics, median (range)
Disease duration, months 5 (3.2-6.8)
Disease Activity Score, 28 joints evaluated 6 (5.1-7.1)
Health Assessment Questionnaire 1.5 (0.9-2.1)
Nº (%) patients with ≥ 1comorbidity 88 (59.1)
Median (range) of comorbidity/patient 1 (0–1)
N° = Number.
SD = Standard deviation.
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their counterparts, Table 3. Also, they selected more fre-
quently responses “Slightly, Moderately, Quite a bit or
Extremely” to the question (Number 8) “In the past six
months, how much difficulty did you had to find your
arthritis medication at the drugstore?” and to the ques-
tion (Number 9)” In the past 6 months, how much ex-
pensive did you consider was you arthritis medication?”
(Table 3).
Multivariate analysis showed that years of formal edu-
cation (OR: 1.12, 95% CI: 1.1-1.24, p = 0.03), perception
of at least some difficulty to find arthritis medication
(OR: 5.68, 95% CI: 2.48-13, p = 0.000) and perception
that arthritis medication is expensive (OR: 5.27, 95% CI:2.1-13.84, p = 0.001) at the first evaluation of patient’s
therapy behavior were all predictors of NP (age and gen-
der correction was done).
Predictors of recurrent NP
As it has been demonstrated that persistence impacts
outcomes, we ought to define if there was a particular
number of times a patient had to be NP in order to have
greater disease activity and disability. Recurrent-NP
patients had greater disease activity and disability than
their counterparts, (mean ± SD) cumulative DAS28:
3.7 ± 2 vs. 2.9 ± 1.7, p = 0.04 and cumulative HAQ:
0.3 ± 0.2 vs. 0.1 ± 0.1, p = 0.05.
Among the 99 NP patients, 25 (25.3%) were recurrent-
NP and their characteristics were compared to their
counterparts (74 patients); no differences were found be-
tween groups besides those related to disease activity
and disability. The number of patients with DAS28 re-
mission was lower among recurrent-NP patients (45 vs.
8, p = 0.002) as was the number of patients with disease
activity improvement according to European League
Against Rheumatism (EULAR) categories (11 vs. 62,
p = 0.000).
Logistic regression models were constructed in order
to investigate predictors on recurrent-NP; in all of them,
any possible combination of the 15 patient’s motivations
of NP when referred at first evaluation of compliance
were included. Models yield similar results: the combin-
ation of both reasons of NP (“Because it was not avail-
able at the drugstore” and “Because the medication is
very expensive”) when mentioned at the first time the
CQ is applied was the only variable to predict recurrent
NP, OR: 4.8, 95%CI: 1.1-20.8, p = 0.04. Results were simi-
lar after correction for disease duration, gender and age
at disease onset.
Discussion
From the perspective of healthcare providers, thera-
peutic compliance is a major clinical issue in RA
patients as it impacts disease’s outcomes [5,17,18]. Inad-
equate medication adherence (which includes three
major components: persistence, initiation adherence and
execution adherence) causes an increased financial
burden for society as it has been associated to excess
emergency care visits and hospitalizations, higher treat-
ment costs and loss of productivity. Furthermore, as a
result of undetected or unreported therapeutic non-
compliance, physicians may change the regimen, which
may increase the cost or complexity of the treatment
and eventually the incidence of adverse events. One
logical target in trying to complete the riddle of thera-
peutic non-compliance in RA would be to identify most
common associated factors from the patient’s perspec-
tive and to identify predictors as we did in the present
Table 2 Patient’s motivations for non-persistence and comparison of patient’s motivations during remission and
disease activity states
N° (%) of times a
motivation is referred
among 330 CQ
N° (%) of times a motivation is
referred among 109 CQ applied in
remission states
N° (%) of times a motivation is




Because I forget to take it 143 (43.3) 43 (39.4) 100 (45.2) 0.38
Because I had no money to buy it 112 (33.9) 41 (37.6) 71 (32.1) 0.39
Because it was not available at the
drugstore
100 (30.3) 32 (29.4) 68 (30.8) 0.89
Because I did not buy it 98 (29.7) 30 (27.5) 68 (30.8) 0.63
Because I was not at home when I
had to take my medication
91 (27.6) 22 (20.2) 69 (31.2) 0.05
Because the medication is very
expensive
79 (23.9) 27 (24.8) 52 (23.5) 0.91
Because I had to do more things
than I usually do through the day
60 (18.2) 14 (12.8) 46 (20.8) 0.10
Because I went out on a trip 40 (12.2) 9 (8.3) 31 (14) 0.18
Because timing/s when my
medication is prescribed is
different from mealtime/s
30 (9.1) 11 (10.1) 19 (8.6) 0.81
Because I am taking a lot of
medication at this time
25 (7.6) 13 (11.9) 12 (5.4) 0.06
Because it may me feel worse
when I take it
23 (7) 9 (8.2) 14 (6.3) 0.68
Because it does not make me feel
better
19 (5.8) 9 (8.2) 10 (4.5) 0.26
Because nobody reminded me to
take my medication
15 (4.6) 1 (0.9) 14 (6.3) 0.05
Because nothing happens if I do
not take it
8 (2.4) 5 (4.6) 13 (5.9) 0.82
Because I did fewer things than I
usually do through the day
5 (1.5) 2 (1.8) 3 (1.4) 0.88
CQ = Compliance Questionnaire.
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Mexican Mestizo early RA patients.
We found that 2 out of 3 patients were classified as
NP. In the literature, different studies have targeted ad-
herence to DMARDs [5,6,9,10,13,15,16,24] and shown
that the extent to which patients adhere to DMARD
therapy varies between underuse and overuse. Such vari-
ations may be explained by differences in sample’s size,
methods capturing medication adherence, variable dis-
ease duration, follow-up, disease activity and therapeutic
modalities, although studies confirm that adherence in
RA is suboptimal. An important point to consider is that
medication adherence is a dynamic feature, not stable
over time. We found that 25% of our patients were con-
sistently NP similar to have been reported in longitu-
dinal studies performed in other RA populations
[5,14,25].
Factors identified from studies and reviews with poor
compliance may be grouped into several categories, and
divided into 5 domains according to the World HealthOrganization: namely patient-centered factors, therapy-
related factors, healthcare systems factors, social and
economic factors, and disease factors [20,26]. In our
study, NP patients were directed to select at least one
factor from a list; factors were included in the list as all
of them have been shown to impact compliance in
different populations [17,20,26]. Most frequent patient’s
motivations for NP were forgetfulness, lack of financial
resources and lack of availability at the drug store.
Forgetfulness is a widely reported factor that causes
non-compliance with both, medication and clinical
appointments in different populations, including Mexican
patients with type2-diabetes [27,28]. Meal frequency has
been shown to be an effective tool to remind the patient
to take his medications in Japanese patients [29] and this
strategy could be intensified in order to improve compli-
ance. Interestingly, in our study “forgetfulness” was highly
correlated to the motivation “Because timing/s when my
medication is prescribed is different from mealtime/s
“(Rho: 0.92, p = 0.001, data not shown). Also, written
Table 3 Differences between non-persistent (NP) and persistent patients
NP patients Persistent patients p
N = 99 N = 50
(Mean ± SD) years of formal education 11.4 ± 3.8 10 ± 3.9 0.03
(Mean ± SD) months of follow-up 62.7 ± 26.4 50.1 ± 29.5 0.009
N° (%) of patients with ACCP when entering the Clinic 83 (84) 34 (68) 0.04
(Mean ± SD) cumulative DAS28 3.1 ± 1.8 2.2 ± 1.1 0.001
(Mean ± SD) cumulative HAQ 0.4 ± 0.4 0.3 ± 0.3 0.03
N° (%) of patients who selected responses “Slightly, Moderately,
Quite a bit or Extremely” to the question (Number 8),
57 (57) 20 (39.5) 0.000
“In the past six months, how much difficulty did you had to
find your arthritis medication at the drugstore?”
N° (%) of patients who selected responses “Slightly, Moderately,
Quite a bit or Extremely” to the question (Number 9),
92 (93) 42 (80) 0.002
In the past 6 months, how much expensive did you consider
was you arthritis medication
NP = Non-persistent.
N° = Number.
ACCP = Antibodies to cyclic citrullinated peptides.
DAS28 = Disease activity score (28 joints evaluated).
HAQ = Health assessment questionnaire.
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tients to take their medications and we recommend it im-
plementation for every patient, and at every appointment.
Patient’s perception of at least “some difficulty to find
arthritis medication” (previously reported as lack of
availability at the drug store) and that “arthritis medica-
tion is expensive” (lack of financial resources) were
among the most frequent motivations for NP; when both
of them were selected at the first evaluation of patient’s
compliance, they predicted NP (in addition to a higher
education level) and also recurrent- NP. Cost is a crucial
issue in patient’s compliance especially for patients with
chronic diseases [28,30]. A number of studies have
shown that patients who had no insurance cover or who
had low incomes (as our population of patients who had
to pay for their medication) are more likely to be non-
compliant when compared to patients with health insur-
ance or relatively high incomes [27,31-34]. In RA
patients, inadequate or nonexistent reimbursement by
health insurance plans has shown to negatively affect
adherence to biologics [16]. Also, among the identified
health care systems factors that contribute to poor
compliance are lack of availability and accessibility to
healthcare [28]; a significant percentage of our patients
selected lack of availability of the medication which is
related to the former. Finally, regarding education level,
intuitively it may be expected that patients with higher
educational level should have better knowledge about
the disease and therapy benefits and accordingly better
compliance. García-González et al. [10] found an associ-
ation between lower education and lower adherence in
102 ethnically diverse patients from Texas, amongwhom 72 had RA. However, similar to our findings other
researchers have shown that non-RA patients with lower
educations levels have better compliance [35,36]. One
possible explanation may be that patients with lower
education level might have more trust in physician’s
advice. DiMatteo proposed that even highly educated
patients may not understand their conditions and the
benefits of being compliant [37].
In our study, most frequent patient’s motivations for
NP were “unintentional” motivations. As opposed to
intentional motivations, they reflect a person’s ability
and skill at medicine taking, including forgetting, poor
manual dexterity, losing medicines or not being able to
afford them. Meanwhile, intentional non-adherence is a
behavior driven by the decision not to take medicines
[11,25,38]; drivers of this decision have been suggested
to be based on patient’s beliefs about its illness and its
treatment, which can be further categorized as perceived
benefits and perceived concerns [25]. Neame et al. re-
ported that most people with RA had positive beliefs re-
garding the necessity of their medication but levels of
concern were also high and were positively associated to
poor compliance as 91% of non-adherent RA patients
had at least one concern about potential adverse events
[39]. Besides the valuable conceptual distinction between
intentional and non-intentional motivations of non-
adherence in RA patients, a practical approach to poor
patient’s medication behavior will be to identify individ-
ual main drivers of poor compliance and tailor the
content of the adherence-improving-intervention to the
individual patient’s motivation of non-adherence [40].
This comprehensive strategy may be more effective that
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that have shown inconsistent and limited effects
[41-43]; furthermore, it can be applied in our popula-
tion as 79% of our patients selected non-intentional
motivations and among them, 66% selected exclusively
non-intentional motivations during their follow-up
meanwhile 28% selected both, intentional and
non-intentional motivations (data not shown). This
finding is in agreement with the fact that there were no
major differences between active and inactive patients
with NP.
Some limitations of the study need to be addressed.
We did not use a well-validated questionnaire scale to
assess persistence; we applied a short-patient-oriented
questionnaire, locally designed which has shown ad-
equate internal consistency, high sensitivity and satis-
factory specificity to detect persistence on DMARDs
[17]. We did analyze neither the construct of adher-
ence nor major factors associated. This study was done
in an inception cohort of early RA patients, with
particular socio-demographic characteristics, ethnicity,
treatment and health system and our results may not
be generalized to RA populations with different char-
acteristics [4].
Compliance with medication is a dynamic process
and fluctuates over time; with a more extended length
of follow-up, patients formerly classified as persistent
with therapy may become non-persistent. We limited
the study of factors associated to medication persist-
ence, to patient’s motivations; ultimately, it is the
patient who decides whether or not to take his/her
medication as prescribed, and non adherent patient’s
opinion are essential in order to design effective inter-
ventions. Finally, we investigate a limited number of
patient’s motivations for non-persistence with medica-
tion although they were selected based on the existing
literature.Conclusions
Almost half of Mexican Mestizo patients with early RA
and partial health coverage do not take their disease
modifying anti-rheumatic drugs as directed. Most fre-
quent patient’s motivations for non persistence were
non-intentional motivations as forgetfulness, lack of
financial resources and lack of availability at the drug
store. When patients identified concomitantly “some
difficulty to find arthritis medication and that arthritis
medication is expensive” at their first evaluation of
compliance with therapy they may be at risk of non-
persistence during their follow-up and of deleterious
outcomes. Health systems should provide (first line)
treatment for RA as a strategy to improve compliance
with therapy and clinical outcomes.Additional file
Additional file 1: Compliance Questionnaire.
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